CorMedix Reaffirms 2026 Revenue Guidance of $325 Million to $345 Million

CorMedix Therapeutics reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026. The company also reaffirmed its previously issued full-year 2026 total revenue guidance of between $325 million and $345 million. This update was provided in advance of a scheduled conference call on November 12, 2026, where the company intends to discuss its complete quarterly financial performance.